// App-Quantinova.ai

2938 : Ibrutinib Plus Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 Sympatico Study

Researchers

Presenter

  • Constantine S. Tam

Principal Investigators

  • Radhakrishnan Ramchandren

  • Robert Chen

  • Lionel Karlin

  • Geoffrey Chong

  • Wojciech Jurczak

  • Ka Lung Wu

  • Mark Bishton

  • Graham P. Collins

  • Paul Eliadis

  • Frdric Peyrade

  • Edith Szafer-Glusman

  • Yihua Lee

  • Karl Eckert

  • Jutta K. Neuenburg

  • Michael Wang

Medical Centers

  • Peter MacCallum Cancer Center, Royal Melbourne Hospital, and University of Melbourne ,Melbourne,Australia

  • University of Tennessee, Knoxville, TN

  • City of Hope National Medical Center, Duarte, CA

  • Centre Hospitalo-Universitaire Lyon Sud, Lyon, France

  • Olivia Newton-John Cancer Centre, Victoria, Australia

  • The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw,Warsaw,Poland

  • Ziekenhuis Netwerk Antwerpen Stuivenberg,Antwerp,Belgium

  • Nottingham City Hospital, Nottingham, United Kingdom

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Icon Cancer Centre South Brisbane, South Brisbane, Australia

  • Centre Antoine-Lacassagne, Nice, France

  • Pharmcyclics LLC, an AbbVie Company, Sunnyvale, CA

  • Department of Lymphoma and Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX

Locations

  • Australia

  • United States

  • France

  • Poland

  • Belgium

  • United Kingdom

Companies

  • Pharmacyclics LLC

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Mantle cell lymphoma

Biomarkers

  • Bruton tyrosine kinase

  • RNA-binding protein FUS/TLS

  • Tumor protein p53

Drug/Treatment

  • Venetoclax

  • Ibrutinib

  • TP53

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

Phase

  • III

Study Id's

  • NCT03112174

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved